A phase 2 study of encorafenib in combination with binimetinib for Chinese participants with BRAFV600E mutated metastatic non-small cell lung cancer: Results from the OCEAN II study

Study limitation reported by the research below: “The study population is exclusively Chinese patients; distinct genomic or disease characteristics noted by the authors may limit direct extrapolation to other ethnic groups.”